Global Neuroblastoma Treatment Market

Neuroblastoma Treatment Comprehensive Study by Type (Chemotherapy), Application (Hospitals, Clinics, Others), Treatment Type (Combination Chemotherapy, Monoclonal Antibody Therapy, Vaccine Therapy, Others) Players and Region - Global Market Outlook to 2027

Neuroblastoma Treatment Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Neuroblastoma is cancer most commonly affects children age of 5 or younger, and rarely occur in older children. It develops from immature nerve cells found in several areas of the body. It most commonly arises in and around the adrenal glands, which have similar origins to nerve cells and sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the neck, chest, and near the spine, where groups of nerve cells exist. Some forms of neuroblastoma go away on their own, while others may require various treatments. There are different types of treatments are available such as combination chemotherapy, monoclonal antibody therapy, vaccine therapy, and others. The rising incidences of cancer worldwide is one of the major factor contributing to the growth of the market. Also, Stay up-to-date with latest research insights on "Pediatric Neuroblastoma Treatment Share & Growth Analysis".

Highlights from Neuroblastoma Treatment Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
Largest MarketNorth America
Forecast Value (2027)USD 1.25 Billion
UnitValue (USD Billion)
CAGR9.0%


The key Players profiled in the report are Seattle Children’s (United States), CureSearch (United States), Texas Children’s (United States), NANT (United States), The Children’s Hospital of Philadelphia (United States), Boston Children's Hospital (United States), Children’s Oncology Group (United States), Memorial Sloan Kettering Cancer Center (United States), UCSF Benioff Children's Hospital (United States) and The Royal Marsden (United Kingdom). Additionally, other players that are part of this comprehensive study are St. Jude Children's Research Hospital (United States), Apollo Hospitals Enterprise Ltd. (India) and Max Healthcare (India).

Geographic Breakdown and Segment Analysis
The Global Neuroblastoma Treatment market presents a comprehensive analysis of the Neuroblastoma Treatment market by product type (Chemotherapy), by end-user/application (Hospitals, Clinics and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Neuroblastoma Treatment industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the North America holds majority of market share of the Neuroblastoma Treatment market

Analyst at AMA have segmented the market study of Global Neuroblastoma Treatment market by Type, Application and Region. On the basis of Type, Combination Chemotherapy are dominating the market in the year 2021.

Neuroblastoma Treatment Market Dynamics:
AttributesDetails
Growth Drivers
  • The Rising Incidences of Cancer Worldwide
  • Growing Healthcare Expenditure among the Globe
Influencing Trends
  • Increased Cancer Research and Development Activities
  • Rise in the Awareness about Cancer Treatment among People
Restraints
  • A High cost of the Treatment
Gaps & Opportunities
  • The Increasing Incidences of Neuroblastoma from Developing Regions
  • Medical Tourism Can Open New Avenues for the Neuroblastoma Treatment Providers


Market Developments Activities:
Recently, researchers at Sahlgrenska Academy in Gothenburg and Karolinska Institute, among others, have identified two new significant biomarkers for childhood cancer neuroblastoma. and On 29 Nov. 2018, United Therapeutics Corporation has announced that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.



The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations

Key Target Audience
Neuroblastoma Treatments Provider, Research Institutes, Regulatory & Government Bodies, Industry Associations, End Users and Others

Report Objectives / Segmentation Covered

By Type
  • Chemotherapy
By Application
  • Hospitals
  • Clinics
  • Others
By Treatment Type
  • Combination Chemotherapy
  • Monoclonal Antibody Therapy
  • Vaccine Therapy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Incidences of Cancer Worldwide
      • 3.2.2. Growing Healthcare Expenditure among the Globe
    • 3.3. Market Challenges
      • 3.3.1. High Cost of the Treatments
    • 3.4. Market Trends
      • 3.4.1. Increased Cancer Research and Development Activities
      • 3.4.2. Rise in the Awareness about Cancer Treatment among People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuroblastoma Treatment, by Type, Application, Treatment Type and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Neuroblastoma Treatment (Value)
      • 5.2.1. Global Neuroblastoma Treatment by: Type (Value)
        • 5.2.1.1. Chemotherapy
      • 5.2.2. Global Neuroblastoma Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Neuroblastoma Treatment by: Treatment Type (Value)
        • 5.2.3.1. Combination Chemotherapy
        • 5.2.3.2. Monoclonal Antibody Therapy
        • 5.2.3.3. Vaccine Therapy
        • 5.2.3.4. Others
      • 5.2.4. Global Neuroblastoma Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Neuroblastoma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Seattle Children’s (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CureSearch (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Texas Children’s (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NANT (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. The Children’s Hospital of Philadelphia (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boston Children's Hospital (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Children’s Oncology Group (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Memorial Sloan Kettering Cancer Center (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UCSF Benioff Children's Hospital (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. The Royal Marsden (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neuroblastoma Treatment Sale, by Type, Application, Treatment Type and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Neuroblastoma Treatment (Value)
      • 7.2.1. Global Neuroblastoma Treatment by: Type (Value)
        • 7.2.1.1. Chemotherapy
      • 7.2.2. Global Neuroblastoma Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Neuroblastoma Treatment by: Treatment Type (Value)
        • 7.2.3.1. Combination Chemotherapy
        • 7.2.3.2. Monoclonal Antibody Therapy
        • 7.2.3.3. Vaccine Therapy
        • 7.2.3.4. Others
      • 7.2.4. Global Neuroblastoma Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuroblastoma Treatment: by Type(USD Billion)
  • Table 2. Neuroblastoma Treatment Chemotherapy , by Region USD Billion (2016-2021)
  • Table 3. Neuroblastoma Treatment: by Application(USD Billion)
  • Table 4. Neuroblastoma Treatment Hospitals , by Region USD Billion (2016-2021)
  • Table 5. Neuroblastoma Treatment Clinics , by Region USD Billion (2016-2021)
  • Table 6. Neuroblastoma Treatment Others , by Region USD Billion (2016-2021)
  • Table 7. Neuroblastoma Treatment: by Treatment Type(USD Billion)
  • Table 8. Neuroblastoma Treatment Combination Chemotherapy , by Region USD Billion (2016-2021)
  • Table 9. Neuroblastoma Treatment Monoclonal Antibody Therapy , by Region USD Billion (2016-2021)
  • Table 10. Neuroblastoma Treatment Vaccine Therapy , by Region USD Billion (2016-2021)
  • Table 11. Neuroblastoma Treatment Others , by Region USD Billion (2016-2021)
  • Table 12. South America Neuroblastoma Treatment, by Country USD Billion (2016-2021)
  • Table 13. South America Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 14. South America Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 15. South America Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 16. Brazil Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 17. Brazil Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 18. Brazil Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 19. Argentina Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 20. Argentina Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 21. Argentina Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 22. Rest of South America Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 23. Rest of South America Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 24. Rest of South America Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 25. Asia Pacific Neuroblastoma Treatment, by Country USD Billion (2016-2021)
  • Table 26. Asia Pacific Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 27. Asia Pacific Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 28. Asia Pacific Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 29. China Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 30. China Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 31. China Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 32. Japan Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 33. Japan Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 34. Japan Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 35. India Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 36. India Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 37. India Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 38. South Korea Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 39. South Korea Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 40. South Korea Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 41. Taiwan Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 42. Taiwan Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 43. Taiwan Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 44. Australia Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 45. Australia Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 46. Australia Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 47. Rest of Asia-Pacific Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 48. Rest of Asia-Pacific Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 49. Rest of Asia-Pacific Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 50. Europe Neuroblastoma Treatment, by Country USD Billion (2016-2021)
  • Table 51. Europe Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 52. Europe Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 53. Europe Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 54. Germany Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 55. Germany Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 56. Germany Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 57. France Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 58. France Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 59. France Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 60. Italy Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 61. Italy Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 62. Italy Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 63. United Kingdom Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 64. United Kingdom Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 65. United Kingdom Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 66. Netherlands Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 67. Netherlands Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 68. Netherlands Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 69. Rest of Europe Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 70. Rest of Europe Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 71. Rest of Europe Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 72. MEA Neuroblastoma Treatment, by Country USD Billion (2016-2021)
  • Table 73. MEA Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 74. MEA Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 75. MEA Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 76. Middle East Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 77. Middle East Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 78. Middle East Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 79. Africa Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 80. Africa Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 81. Africa Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 82. North America Neuroblastoma Treatment, by Country USD Billion (2016-2021)
  • Table 83. North America Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 84. North America Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 85. North America Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 86. United States Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 87. United States Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 88. United States Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 89. Canada Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 90. Canada Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 91. Canada Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 92. Mexico Neuroblastoma Treatment, by Type USD Billion (2016-2021)
  • Table 93. Mexico Neuroblastoma Treatment, by Application USD Billion (2016-2021)
  • Table 94. Mexico Neuroblastoma Treatment, by Treatment Type USD Billion (2016-2021)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Neuroblastoma Treatment: by Type(USD Billion)
  • Table 106. Neuroblastoma Treatment Chemotherapy , by Region USD Billion (2022-2027)
  • Table 107. Neuroblastoma Treatment: by Application(USD Billion)
  • Table 108. Neuroblastoma Treatment Hospitals , by Region USD Billion (2022-2027)
  • Table 109. Neuroblastoma Treatment Clinics , by Region USD Billion (2022-2027)
  • Table 110. Neuroblastoma Treatment Others , by Region USD Billion (2022-2027)
  • Table 111. Neuroblastoma Treatment: by Treatment Type(USD Billion)
  • Table 112. Neuroblastoma Treatment Combination Chemotherapy , by Region USD Billion (2022-2027)
  • Table 113. Neuroblastoma Treatment Monoclonal Antibody Therapy , by Region USD Billion (2022-2027)
  • Table 114. Neuroblastoma Treatment Vaccine Therapy , by Region USD Billion (2022-2027)
  • Table 115. Neuroblastoma Treatment Others , by Region USD Billion (2022-2027)
  • Table 116. South America Neuroblastoma Treatment, by Country USD Billion (2022-2027)
  • Table 117. South America Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 118. South America Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 119. South America Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 120. Brazil Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 121. Brazil Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 122. Brazil Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 123. Argentina Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 124. Argentina Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 125. Argentina Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 126. Rest of South America Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 127. Rest of South America Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 128. Rest of South America Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 129. Asia Pacific Neuroblastoma Treatment, by Country USD Billion (2022-2027)
  • Table 130. Asia Pacific Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 131. Asia Pacific Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 132. Asia Pacific Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 133. China Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 134. China Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 135. China Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 136. Japan Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 137. Japan Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 138. Japan Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 139. India Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 140. India Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 141. India Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 142. South Korea Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 143. South Korea Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 144. South Korea Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 145. Taiwan Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 146. Taiwan Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 147. Taiwan Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 148. Australia Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 149. Australia Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 150. Australia Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 151. Rest of Asia-Pacific Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 152. Rest of Asia-Pacific Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 153. Rest of Asia-Pacific Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 154. Europe Neuroblastoma Treatment, by Country USD Billion (2022-2027)
  • Table 155. Europe Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 156. Europe Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 157. Europe Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 158. Germany Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 159. Germany Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 160. Germany Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 161. France Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 162. France Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 163. France Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 164. Italy Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 165. Italy Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 166. Italy Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 167. United Kingdom Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 168. United Kingdom Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 169. United Kingdom Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 170. Netherlands Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 171. Netherlands Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 172. Netherlands Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 173. Rest of Europe Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 174. Rest of Europe Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 175. Rest of Europe Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 176. MEA Neuroblastoma Treatment, by Country USD Billion (2022-2027)
  • Table 177. MEA Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 178. MEA Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 179. MEA Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 180. Middle East Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 181. Middle East Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 182. Middle East Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 183. Africa Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 184. Africa Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 185. Africa Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 186. North America Neuroblastoma Treatment, by Country USD Billion (2022-2027)
  • Table 187. North America Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 188. North America Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 189. North America Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 190. United States Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 191. United States Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 192. United States Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 193. Canada Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 194. Canada Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 195. Canada Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 196. Mexico Neuroblastoma Treatment, by Type USD Billion (2022-2027)
  • Table 197. Mexico Neuroblastoma Treatment, by Application USD Billion (2022-2027)
  • Table 198. Mexico Neuroblastoma Treatment, by Treatment Type USD Billion (2022-2027)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuroblastoma Treatment: by Type USD Billion (2016-2021)
  • Figure 5. Global Neuroblastoma Treatment: by Application USD Billion (2016-2021)
  • Figure 6. Global Neuroblastoma Treatment: by Treatment Type USD Billion (2016-2021)
  • Figure 7. South America Neuroblastoma Treatment Share (%), by Country
  • Figure 8. Asia Pacific Neuroblastoma Treatment Share (%), by Country
  • Figure 9. Europe Neuroblastoma Treatment Share (%), by Country
  • Figure 10. MEA Neuroblastoma Treatment Share (%), by Country
  • Figure 11. North America Neuroblastoma Treatment Share (%), by Country
  • Figure 12. Global Neuroblastoma Treatment share by Players 2021 (%)
  • Figure 13. Global Neuroblastoma Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Neuroblastoma Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Seattle Children’s (United States) Revenue, Net Income and Gross profit
  • Figure 17. Seattle Children’s (United States) Revenue: by Geography 2021
  • Figure 18. CureSearch (United States) Revenue, Net Income and Gross profit
  • Figure 19. CureSearch (United States) Revenue: by Geography 2021
  • Figure 20. Texas Children’s (United States) Revenue, Net Income and Gross profit
  • Figure 21. Texas Children’s (United States) Revenue: by Geography 2021
  • Figure 22. NANT (United States) Revenue, Net Income and Gross profit
  • Figure 23. NANT (United States) Revenue: by Geography 2021
  • Figure 24. The Children’s Hospital of Philadelphia (United States) Revenue, Net Income and Gross profit
  • Figure 25. The Children’s Hospital of Philadelphia (United States) Revenue: by Geography 2021
  • Figure 26. Boston Children's Hospital (United States) Revenue, Net Income and Gross profit
  • Figure 27. Boston Children's Hospital (United States) Revenue: by Geography 2021
  • Figure 28. Children’s Oncology Group (United States) Revenue, Net Income and Gross profit
  • Figure 29. Children’s Oncology Group (United States) Revenue: by Geography 2021
  • Figure 30. Memorial Sloan Kettering Cancer Center (United States) Revenue, Net Income and Gross profit
  • Figure 31. Memorial Sloan Kettering Cancer Center (United States) Revenue: by Geography 2021
  • Figure 32. UCSF Benioff Children's Hospital (United States) Revenue, Net Income and Gross profit
  • Figure 33. UCSF Benioff Children's Hospital (United States) Revenue: by Geography 2021
  • Figure 34. The Royal Marsden (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. The Royal Marsden (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Global Neuroblastoma Treatment: by Type USD Billion (2022-2027)
  • Figure 37. Global Neuroblastoma Treatment: by Application USD Billion (2022-2027)
  • Figure 38. Global Neuroblastoma Treatment: by Treatment Type USD Billion (2022-2027)
  • Figure 39. South America Neuroblastoma Treatment Share (%), by Country
  • Figure 40. Asia Pacific Neuroblastoma Treatment Share (%), by Country
  • Figure 41. Europe Neuroblastoma Treatment Share (%), by Country
  • Figure 42. MEA Neuroblastoma Treatment Share (%), by Country
  • Figure 43. North America Neuroblastoma Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Seattle Children’s (United States)
  • CureSearch (United States)
  • Texas Children’s (United States)
  • NANT (United States)
  • The Children’s Hospital of Philadelphia (United States)
  • Boston Children's Hospital (United States)
  • Children’s Oncology Group (United States)
  • Memorial Sloan Kettering Cancer Center (United States)
  • UCSF Benioff Children's Hospital (United States)
  • The Royal Marsden (United Kingdom)
Additional players considered in the study are as follows:
St. Jude Children's Research Hospital (United States) , Apollo Hospitals Enterprise Ltd. (India) , Max Healthcare (India)
Select User Access Type

Key Highlights of Report


Jul 2022 176 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuroblastoma Treatment Market Quantitative research analysis
Global Neuroblastoma Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2027
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • High Cost of the Treatments

Know More About Global Neuroblastoma Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Drug Abuse Testing Comprehensive Study by Type (Analyzers, Rapid Testing Devices, Consumables, Laboratory Services), Sample (Urine, Oral Fluid, Breath, Hair, Others), End User (Workplaces & Schools, ...
$ 3450
Healthcare Automatic Identification & Data Capture (AIDC) Comprehensive Study by Type (Barcode Printers, Market by technology, Dot matrix Printer, Laser Printer, Ink jet printer), Application (Clinic...
$ 3750
Hospital Staffing Comprehensive Study by Type (Emergency Department, Home Care Services), Application (Hospitals, Clinics, Ambulatory Centers, Home Care Settings), Staffing Service (Travel Nurse, Per...
$ 3350
Chemoinformatics Comprehensive Study by Application (Chemical Analysis, Drug Discovery, Drug Validation, Other Applications) Players and Region - Global Market Outlook to 2030
$ 3500
Healthcare Staffing Comprehensive Study by Type (Travel Nurse Staffing, Per Diem Nurse Staffing, Locum Tenens Staffing, Allied Health Care Staffing, Others), Application (Hospitals, Clinics, Ambulato...
$ 4000
Cardiac Ablation Devices Comprehensive Study by Type (Electrophysiology Lab Devices, Diagnostic EP Catheters, Cardiac Ablation Catheters), Application (Hospital, Clinics), Distribution Channel (Onlin...
$ 3500